Allarity Therapeutics is a clinical-stage precision medicine company actively advancing stenoparib, an orally available, small molecule inhibitor for patients with advanced recurrent ovarian cancer. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on NASDAQ, Allarity (ALLR) is headquartered in Boston, MA, while maintaining an R&D facility in Hoersholm, Denmark. Allarity is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
Our Lead Program: Stenoparib
Stenoparib is at the forefront of Allarity’s mission to personalize cancer care. Here’s why it’s our lead program:
Versatility: While our current Phase 2 study is focused on advancing stenoparib toward eventual approval in ovarian cancer, we believe the drug’s potential may extend to multiple cancer types, making it a versatile weapon against cancer.

Molecular model of Allarity’s lead asset: stenoparib
Our Pipeline
Allarity’s focused pipeline is centered on stenoparib, an orally available small molecule. Its unique dual-action mechanism inhibits both PARP1/2 and telomerase maintenance enzymes.
Our Platform
Our DRP® Technology is a first-in-class, highly validated diagnostic platform that models human tumor biology and can help predict whether a cancer patient will respond or not to a particular drug.
Publications
Results from our DRP® platform have been published in numerous peer-reviewed scientific journals, highlighting the predictive capabilities of our proprietary approach to precision medicine.
No two people are the same. Neither are their cancers. DRP® technology is a unique and best-in-class proprietary diagnostic platform built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types, and refined with actual gene expression data from more than 3,000 patient tumors